Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2005-10, Vol.19 (10), p.1835-1838
Hauptverfasser:	Dengler, J, von Bubnoff, N, Decker, T, Peschel, C, Duyster, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology B-Lymphocytes - drug effects B-Lymphocytes - metabolism BCR-ABL protein Benzamides Cancer Research Cells, Cultured Critical Care Medicine Drug Resistance, Neoplasm Drug Therapy, Combination Everolimus Fusion protein Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Hematology Imatinib Imatinib Mesylate Immunosuppressive Agents - pharmacology Intensive Internal Medicine Medicine Medicine & Public Health Mice Mutation - genetics Oncology Piperazines - administration & dosage Pyrimidines - administration & dosage Rapamycin Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - pharmacology spotlight-correspondence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!